Key Segmentation
By Product
-
Iodinated Contrast Media
-
Gadolinium-Based Contrast Media
-
Microbubble Contrast Media
-
Barium-Based Contrast Media
-
Other Products
By Modality
-
X-ray and CT
-
MRI
-
Ultrasound
By Route of Administration
-
Intravascular
-
Oral
-
Rectal
-
Other Routes
By Application
-
Cardiovascular Disorders
-
Neurological Disorders
-
Oncology
-
Gastrointestinal Disorders
-
Other Applications
By End User
-
Hospitals and Clinics
-
Diagnostic Imaging Centers
-
Other End Users
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Bayer AG, GE HealthCare, Bracco Imaging, Guerbet, Lantheus Holdings, Jiangsu Hengrui Pharmaceuticals, Beijing Beilu Pharmaceutical, Azurity Pharmaceuticals and J.B. Chemicals & Pharmaceuticals.
Key opportunities include low dose gadolinium agents, gadolinium-free MRI agents, microbubble products for ultrasound and growing scanner access in emerging markets.
Rising imaging volumes driven by cancer, cardiovascular disease and population aging are the main growth factor, supported by wider CT and MRI access and new low dose agents.
By Product, the Iodinated Contrast Media segment dominated the market in 2025 with an estimated 66.91% share, supported by routine CT, angiography and interventional procedures.
North America dominated the market with a share of 39.67% in 2025, driven by high CT and MRI volumes, advanced cancer care and early adoption of new agents.